SomaLogic
SomaLogic is a Boulder-based proteomics company using proprietary SOMAmer aptamer technology to measure up to 11,000 proteins from small blood samples via its SomaScan Platform, serving pharmaceutical trial sponsors, national biobanks, and academic researchers; acquired by Illumina in January 2026.
- Company typePrivate
- Founded2000
- HeadquartersBoulder, United States
- Headcount251–500
- GTM typeB2B
- OfferingServices
What SomaLogic does
SomaLogic is a Boulder, Colorado-based protein biomarker discovery and clinical diagnostics company founded in 2000 that built its business around its proprietary SOMAmer (Slow Off-rate Modified Aptamer) chemistry. The company operates the SomaScan Platform, which uses chemically modified DNA aptamers to measure up to 11,000 proteins simultaneously from a 55-µL plasma or serum sample, covering roughly half of the human proteome across a 10-log dynamic range without sample pre-treatment, with industry-leading reproducibility (median CV of approximately 5%). Complementary products include the SomaScan Select 4K Assay for targeted applications, the KREX high-plex antibody profiling technology for immunoproteomics, and SomaSignal Tests as research-use biomarker panels across cardiovascular, neurodegeneration, oncology, and metabolic disease areas.
SomaLogic commercializes this technology through a fee-for-service SomaScan Assay Services operation running out of a CLIA-certified, CAP-accredited laboratory in Boulder, a global network of Authorized Sites providing regional access, direct sales of Single SOMAmer Reagents to platform operators, and data consulting services. Customers include large pharmaceutical trial sponsors (Bristol Myers Squibb, Novo Nordisk, Gilead, Pfizer, Novartis), national genomics and biobank programs (Genomics England, PRECISE-SG100K), academic medical centers, and research consortia. The company has accumulated 3+ billion proteomic measurements, 270,000+ profiled plasma samples, and 1,000+ peer-reviewed publications, with an 89% coverage rate of FDA-approved protein biomarkers and demonstrably higher data completeness (96.2%) than competing antibody-based platforms.
SomaLogic's corporate trajectory has been turbulent: a 2021 SPAC debut, an approximately 80% stock decline due to profitability challenges, a January 2024 merger into Standard BioTools as a wholly owned subsidiary, and ultimately a January 30, 2026 acquisition by Illumina for $350 million in cash plus up to $75 million in performance-based milestones and revenue-based royalties. As of the acquisition, approximately 250 employees and the Boulder facilities transferred to Illumina, and the SomaScan 11K Assay is being rebranded as Illumina SomaScan Discovery within Illumina's multiomics ecosystem alongside its NGS platforms and DRAGEN software. Standard BioTools retained a 2% royalty on SOMAmer-based NGS library preparation kits for 10 years post-close.
SomaLogic firmographics
Firmographics- Name
- SomaLogic
- Legal name
- SomaLogic Operating Co., Inc.
- Website
- https://somalogic.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Acquired
- Headcount range
- 251–500 employees
- Short description
- SomaLogic is a Boulder-based proteomics company using proprietary SOMAmer aptamer technology to measure up to 11,000 proteins from small blood samples via its SomaScan Platform, serving pharmaceutical trial sponsors, national biobanks, and academic researchers; acquired by Illumina in January 2026.
- Ownership category
- akta.pro rank
SomaLogic industry classification
Industry- Product category
- Clinical Proteomics
- NAICS
- Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Proteomics & Biomarker Analytical Testing (HLAGADAG)
- akta.pro secondary industries
- Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)
Keywords
Where SomaLogic is headquartered
LocationHeadquarters
- HQ city
- Boulder
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
SomaLogic business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- SomaScan Assay Services: Fee-for-service proteomics platform provided at SomaLogic's CLIA-certified, CAP-accredited laboratory. Customers send samples for processing and receive proteomic data. Services also available through Authorized Sites worldwide.
- Reagent Consumables: Single SOMAmer Reagents sold to customers who operate their own SomaScan platforms or Authorized Sites for proteomics analysis.
- SomaScan Data Consulting Services: Bioinformatics and data analysis services to help customers interpret proteomic data and extract biological insights.
- SomaLogic Licensing and Royalties: Standard BioTools retained 2% royalty on SOMAmer-based NGS library preparation kits for 10 years following sale to Illumina. Additional revenue-based royalties may apply from the Illumina acquisition.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Fee-for-service proteomics platform - quote-based pricing |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels4 records
SomaLogic product offering
Product offeringCore offering
SomaLogic provides aptamer-based proteomics products and services built on its proprietary SOMAmer reagent technology. Its core commercial offerings include the SomaScan Platform (11K and Select 4K Assays) for high-multiplex protein measurement, the KREX technology for enhanced detection of low-abundance analytes, fee-for-service SomaScan Assay Services run from a CLIA-certified laboratory, SomaSignal clinical diagnostic tests, and Single SOMAmer Reagents sold to research customers. The offering is targeted at pharmaceutical and biotechnology companies, academic research institutions, national biobanks, and clinical research organizations.
Product overview
SomaLogic offers a unified proteomics platform centered on the SomaScan Platform, which uses proprietary SOMAmer® Reagent aptamer technology to enable high-plex protein measurement. The core portfolio includes the SomaScan 11K Assay (11,000 proteins) and SomaScan Select 4K Assay (4,000 proteins) for broad and targeted proteomic coverage, alongside KREX™ Technology for high-plex antibody profiling. The company operates a fee-for-service model through its CLIA-certified, CAP-accredited laboratory and a global network of Authorized Sites. Supporting products include SomaScan Panels for targeted applications, SomaSignal Tests for biomarker research, and digital tools including the SomaScan Menu database, DataDelve™ Statistics software, and Life Sciences Customer Portal for study management.
Differentiator
Problem solved
Functional benefit
Brands
- SomaScan: Aptamer-based proteomics platform capable of measuring 11,000 proteins from a 55-µL sample. Available in 5K and 11K assay versions.
- SomaScan Assay Services
- SomaSignal Tests
- KREX
- SOMAmer Reagents
Products and services
- SomaScan Platform The SomaScan Platform is SomaLogic's flagship aptamer-based proteomics offering, enabling simultaneous measurement of thousands of protein analytes from small biological samples. It is targeted at pharmaceutical and biotechnology companies, academic medical centers, national biobanks, and clinical research organizations for biomarker discovery, translational research, and clinical proteomics applications.
- SomaScan 11K Assay The SomaScan 11K Assay is a high-multiplex proteomic assay that measures approximately 11,000 protein analytes from a single 55 μL sample with a ~5% median coefficient of variation and a 10-log dynamic range. It is sold to pharmaceutical and biotech R&D teams, academic researchers, and biobank programs for large-scale biomarker discovery and population proteomics studies.
- SomaScan Select 4K Assay The SomaScan Select 4K Assay is a 4,000-analyte configuration of the SomaScan proteomic assay, offering a higher-throughput, focused panel for translational and clinical research. It is targeted at customers needing a more targeted proteomic profile with the reproducibility and scalability of the SomaScan Platform.
- KREX Technology KREX (Kinetic Rate Enhancement) is a proprietary SomaLogic technology that enhances detection of lower-abundance protein analytes, expanding the dynamic range and biological coverage of the SomaScan Platform. It is offered as part of SomaLogic's proteomics solutions for discovery and translational research customers.
- SomaScan Assay Services SomaScan Assay Services is a fee-for-service offering in which SomaLogic runs SomaScan proteomic profiling on customer samples at its CLIA-certified laboratory. The service is targeted at pharmaceutical and biotech sponsors, academic investigators, biobanks, and clinical research organizations that need access to high-multiplex proteomics without internal assay capability.
- SomaSignal Tests SomaSignal Tests are clinical diagnostic tests developed from SomaLogic's proteomics platform, leveraging protein signatures measured by the SomaScan Assay to produce clinical outputs. They are positioned for use by healthcare providers and clinical research customers.
- Single SOMAmer Reagents Single SOMAmer Reagents are individual Slow Off-rate Modified Aptamer reagents sold to research customers for custom assay development, targeted protein measurement, and integration into customer-defined workflows. They are targeted at proteomics researchers and assay developers.
- Illumina Protein Prep Illumina Protein Prep is an NGS-based protein identification kit co-developed with Illumina that allows SOMAmer-captured protein targets to be read out on Illumina sequencing platforms. It is targeted at customers who want to combine aptamer-based protein capture with next-generation sequencing readouts.
Quantifiable outcome
- 96.2% data completeness vs 35-60% for competing platforms in independent comparison study
- +3 more outcomes
Companies that use SomaLogic
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles4 records
SomaLogic technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
SomaLogic partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and major.
- NovartiscoreWorld-class strategic partner collaborating on proteomics research and drug discovery. Novartis utilizes SomaScan Platform for clinical studies in multiple therapeutic areas.
- NEC CorporationcoreStrategic partnership for proteomics applications, combining NEC's technology capabilities with SomaLogic's proteomics platform for data-driven health insights.
- AgilentcoreTechnology partner providing complementary laboratory solutions integrated with SomaLogic's proteomics platform for comprehensive research workflows.
- Leeds Teaching Hospitals NHS TrustcoreStrategic partner in precision medicine research, combining clinical expertise with SomaScan proteomics for disease research and biomarker discovery.
- OtsukacoreStrategic pharmaceutical partnership for proteomics applications in drug development and clinical research across therapeutic areas.
- IlluminacorePartnership began in late 2021 for proteomics co-development. SomaLogic's SomaScan technology integrated with Illumina's NGS ecosystem. Illumina completed acquisition of SomaLogic in January 2026 for $350M upfront plus potential $75M milestones.
- Vanderbilt University Medical CentermajorBioVU biobank providing over 250,000 genomes with rich clinical data for Illumina's Alliance for Genomic Discovery project, with plans to include proteomics and spatial transcriptomics data.
- Alnylam PharmaceuticalsmajorPartner in Alliance for Genomic Discovery expanding genomic dataset to over 250,000 genomes for drug target discovery in diverse populations.
- Genomics EnglandmajorNational genomics program utilizing Illumina Protein Prep proteomics technology for large-scale population health research.
- PRECISE-SG100KmajorSingapore national biobank program integrating proteomics with genomic data for precision medicine research.
Scale indicators10 records
Recent moves6 records
Expansion highlights5 records
SomaLogic competitors and assessment
Company assessmentDirect peers
- Olink Holding (now part of Thermo Fisher Scientific): Olink's proximity extension assay-based Explore and Target platforms are the most direct head-to-head competitor to SomaScan in high-plex plasma proteomics, used by the same pharma trial and biobank customers and benchmarked against SomaScan in published precision studies.
Emerging players
- Seer: Seer's Proteograph product suite uses engineered nanoparticle capture plus mass spectrometry to deliver deep, unbiased plasma proteomics, representing an alternative high-plex approach competing for the same biomarker discovery and population proteomics budgets as SomaScan.
- Quanterix: Quanterix's Simoa single-molecule array technology delivers ultra-sensitive protein detection at lower plex, frequently used in neurodegeneration and oncology biomarker studies that overlap with SomaScan's SomaSignal test menu.
- 10x Genomics: 10x Genomics' single-cell and spatial transcriptomics platforms (Chromium, Xenium, Visium) compete for multi-omic pharma research budgets and increasingly integrate proteomics readouts that overlap with SomaLogic's customer use cases.
Broad incumbents
- Standard BioTools: Standard BioTools was SomaLogic's parent company from January 2024 until the Illumina sale; its mass cytometry (CyTOF) and microfluidics platforms serve overlapping pharma and academic customers, and its Discovery Lab complements SomaScan services for multi-omic profiling.
- Bio-Techne: Bio-Techne offers antibody-based proteomics reagents (including the Simple Western and Ella platforms) and ELISA kits that compete for protein biomarker measurement budgets in pharma and academic labs where SomaScan assays are also used.
- Meso Scale Diagnostics: MSD's electrochemiluminescence-based multiplex immunoassays are widely used in pharma clinical trials and biomarker validation, representing the incumbent high-sensitivity antibody-based alternative to SomaScan's aptamer-based platform.
- Bruker (NanoString Spatial Biology): Bruker's acquisition of NanoString brings the GeoMx and CosMx spatial proteomics platforms into a broader proteomics and life sciences portfolio, competing with SomaScan-adjacent workflows in pharma biomarker discovery and translational research.
- Thermo Fisher Scientific (Life Sciences Mass Spectrometry): Thermo Fisher's Orbitrap mass spectrometry instruments and Olink proteomics franchise (post-acquisition) make it the dominant incumbent in mass spec-based proteomics, an alternative workflow competing for SomaScan's pharma and academic customers.
Others
- Abcam: Abcam supplies antibody-based research reagents and validated assay kits that underpin traditional proteomics workflows; while not a direct SomaScan competitor, it serves the same researcher and pharma customer base for protein biomarker studies.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
SomaLogic social profiles
Digital presenceSomaLogic compliance and trust
Trust signalCompliance6 records
SomaLogic financial estimates
Financial estimateRevenue estimate
Valuation estimate
SomaLogic leadership team
Management profileNumber of profiles
Profiles11 records
SomaLogic subsidiaries and ownership
Company hierarchySubsidiaries1 record
SomaLogic funding detail
Funding detailFunding overview
Funding rounds16 records
Investors37 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SomaLogic M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SomaLogic
What does SomaLogic do?
SomaLogic provides aptamer-based proteomics products and services built on its proprietary SOMAmer reagent technology. Its core commercial offerings include the SomaScan Platform (11K and Select 4K Assays) for high-multiplex protein measurement, the KREX technology for enhanced detection of low-abundance analytes, fee-for-service SomaScan Assay Services run from a CLIA-certified laboratory, SomaSignal clinical diagnostic tests, and Single SOMAmer Reagents sold to research customers. The offering is targeted at pharmaceutical and biotechnology companies, academic research institutions, national biobanks, and clinical research organizations.
Is SomaLogic a public or private company?
SomaLogic is a private company. It is classified as corporate owned and is currently acquired.
When was SomaLogic founded?
SomaLogic was founded in 2000. It employs 251 to 500 people.
Where is SomaLogic based?
SomaLogic is headquartered in Boulder, United States, in the North America region.
How does SomaLogic make money?
Four revenue lines are on record. SomaScan Assay Services are the primary driver. The others are reagent Consumables, somaScan Data Consulting Services and somaLogic Licensing and Royalties.
Who are SomaLogic's main competitors?
Olink Holding (now part of Thermo Fisher Scientific) is listed as a direct peer. Emerging players are Seer, Quanterix and 10x Genomics. Broad incumbents are Standard BioTools, Bio-Techne, Meso Scale Diagnostics, Bruker (NanoString Spatial Biology) and Thermo Fisher Scientific (Life Sciences Mass Spectrometry). Abcam is listed as an others.
Does SomaLogic have an API?
No public API is recorded for SomaLogic.
What industry is SomaLogic in?
SomaLogic's product category is Clinical Proteomics. Its primary akta.pro industry code is HLAGADAG, Proteomics & Biomarker Analytical Testing, with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 6215 and its SIC code is 8071.